Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. (Nasdaq: GANX) is a clinical-stage biotechnology company whose news flow is closely tied to the development of its lead drug candidate, GT-02287, and to progress in its broader allosteric small molecule pipeline. The company focuses on next generation allosteric therapies targeting neurodegenerative diseases, rare genetic disorders and oncology, with a primary emphasis on Parkinson’s disease.
News about Gain Therapeutics frequently covers clinical milestones for GT-02287, including updates from its Phase 1 and Phase 1b studies in people with Parkinson’s disease with or without a GBA1 mutation. Press releases have detailed safety and tolerability findings, exploratory biomarker data such as reductions in glucosylsphingosine (GluSph) in cerebrospinal fluid, and observations related to Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores. These items provide insight into how the company interprets GT-02287’s potential disease-modifying effects and mechanism of action.
Investors and observers can also expect regular announcements on preclinical research and scientific presentations. Gain Therapeutics reports data from preclinical models that explore GCase modulation, mitochondrial and lysosomal health, and neuroprotection in Parkinson’s disease. Poster presentations at scientific meetings, such as Neuroscience conferences and Parkinson’s-focused congresses, are common subjects of the company’s news releases.
Additional news items include corporate updates and financial disclosures, such as quarterly financial results, capital raises, changes in board composition, and shareholder meeting outcomes. The company also issues notices about participation in investor conferences, key opinion leader (KOL) events, and webinars that discuss biomarkers, clinical endpoints and emerging data from GT-02287 studies.
For readers following GANX, the news page provides a centralized view of clinical trial progress, scientific data, regulatory and corporate developments, and event participation related to Gain Therapeutics’ efforts in allosteric small molecule drug development.
Gain Therapeutics, Inc. (Nasdaq: GANX) will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 1:30 PM ET. CEO Eric Richman is set to lead the corporate presentation and host one-on-one meetings during the event, which runs from May 23-25 in Miami, Florida. Gain is known for its innovative drug discovery platform that targets allosteric binding sites to create small molecule treatments for various diseases, including neurodegenerative disorders. A live webcast will be available on their website, and an archived version will follow.
Gain Therapeutics (GANX) reported a net loss of $3.27 million for Q1 2022, improving from a loss of $2.54 million in Q1 2021. Revenue increased to $45,000, driven by collaboration agreements. R&D expenses rose to $1.56 million, while general and administrative costs surged to $1.78 million. The company holds $34.34 million in cash, providing operational runway into the latter half of 2023. Notable preclinical data was presented for its lead candidate GT-02287 targeting Parkinson’s and Gaucher's diseases, suggesting its potential therapeutic benefits.
Gain Therapeutics (Nasdaq: GANX) showcased promising data for its lead compound GT-02329 targeting Gaucher disease at the 1st IWGDD Symposium. The compound boosts GCase levels and activity, effectively reducing toxic substrate accumulation in both human and mouse models. Specifically, the data highlighted increased GCase activity and decreases in glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph). The company aims to further investigate GT-02329's potential as a therapy to alleviate neurological effects associated with Gaucher disease.
Gain Therapeutics, Inc. (Nasdaq: GANX) has announced promising pre-clinical results for its lead compound, GT-02287, targeting Parkinson’s Disease. Presented at the XXVII World Congress on Parkinson’s Disease, the compound successfully penetrates the brain, reduces alpha-synuclein levels, and improves dopamine production in neuronal models. Data showcases its ability to bind with the GCase protein, enhancing lysosomal function. The findings suggest potential disease-modifying effects, positioning GT-02287 as a candidate for clinical advancement this year.
Gain Therapeutics (Nasdaq: GANX) announced that CEO Eric Richman will participate in a fireside chat at the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, from 2:00 to 2:30 p.m. ET. Investors are invited to join via webcast. Gain Therapeutics specializes in drug discovery using its proprietary computational platform, SEE-Tx®, targeting allosteric regulators for various diseases. The company’s lead program focuses on Parkinson’s disease, supported by funding from notable organizations.
Gain Therapeutics (Nasdaq: GANX) presented promising pre-clinical data for its lead candidate GT-02287 at the 2022 Synuclein Meeting in Belgium. The compound enhances GCase levels, promotes lysosomal health, and depletes alpha-synuclein, indicating potential benefits for Parkinson's Disease patients. Key findings include increased GCase activity and neuron survival in relevant models. CEO Eric Richman emphasized the candidate's disease-modifying potential, while the data supports a therapeutic strategy targeting GCase for neurodegenerative diseases.
Gain Therapeutics (Nasdaq: GANX) announced promising pre-clinical data for its Gaucher Disease program, presented at the 2022 Glycolipid and Sphingolipid Biology GRC. The study highlighted that lead compounds significantly increase the levels and activity of the beta-glucocerebrosidase (GCase) protein, enhancing its co-localization with lysosomes and reducing toxic substrate accumulation in neurons. These orally bioavailable compounds may offer a potential treatment for patients with neuronopathic Gaucher disease, addressing a significant unmet medical need.
Gain Therapeutics, Inc. (Nasdaq: GANX) announced significant progress in its lead program for GBA1 Parkinson’s Disease, highlighted by compelling preclinical data and a strong cash position of $36.88 million as of December 31, 2021. The company plans to initiate a first-in-human clinical trial by the end of 2022, following their collaboration with Zentalis Pharmaceuticals to identify novel oncology molecules. Despite increased operating expenses leading to a net loss of $13.89 million, the increase in revenue to $165,000 indicates growing traction in their development efforts.
Gain Therapeutics (Nasdaq: GANX) presented new pre-clinical data at the International Conference on Alzheimer’s and Parkinson’s Diseases demonstrating the potential of their STAR small molecules in treating neurodegenerative diseases. The data shows that enhancing glucocerebrosidase (GCase) activity improves key pathological features linked to Parkinson’s and Alzheimer’s. Results from both Parkinson’s and Alzheimer’s models indicated reductions in neurotoxicity, inflammation, and toxic proteins, suggesting a promising therapeutic avenue for CNS diseases caused by protein misfolding.
Gain Therapeutics (NASDAQ: GANX) announced its participation in key investor and scientific conferences, emphasizing its commitment to neurodegenerative disease research. CEO Eric Richman will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, with a webcast available for investors. Additionally, Gain will showcase scientific data at the AD/PD™ 2022 Conference, running from March 15-20, 2022, and sponsor the Krabbe Translational Research Network Meeting from March 15-18, 2022. The company focuses on innovative treatments using its SEE-Tx™ platform.